Long-term Care, Immunity, and Frailty in Elderly COVID-19
Networks
-
Datasets
-
Variables
-
The primary objective of this study is to prospectively evaluate global and SARS-CoV-2 specific immunity in COVID-19 exposed uninfected, COVID-19 recovered and COVID-19 unexposed long term care facility (LTCF) residents before, during and after SARS-CoV-2 vaccination.
The secondary objectives are to:
1. Measure the breadth, amplitude and frequency of COVID responses in LTCF residents;
2. Compare anti-COVID adaptive responses in cytomegalovirus (CMV) negative and CMV positive LTCF residents as well as those with and without seasonal coronavirus immunity;
3. Describe humoral and cell mediated anti-COVID vaccine induced immunity;
4. Understand relationships between frailty, CMV co-infection and baseline immune phenotype in immune resilient (exposed uninfected) LTCF residents;
5. Describe clinical outcomes with respect to baseline frailty in LTCF associated COVID infection;
6. Biobank samples from a low-prevalence SARS-CoV-2 negative wave 2 longitudinal immunity cohort that can be used to assess difference in frailty or immunity or co-infection parameters between high, medium and low prevalence LTCF populations.
- Start Year
- 2020
- End Year
- 2022
Visit LIFE-CO
| Investigators | Contacts |
|---|---|
|
|
Design
- Study design
- Cohort
- Follow Up
- After the baseline visit, participants were screened before vaccination and then followed-up at 5 timepoints: pre-boost (2-4 weeks post first dose), 1 month, 3 months, 6 months and 1 year post-boost.
Recruitment
- Recruitment Target
-
- Individuals
Number of Participants
- Number of Participants
- 358
- Number of Participants with Biological Samples
- 358
- Supplementary Information
-
COVID-19 exposed uninfected: 48 participants
COVID-19 recovered: 60 participants
COVID-19 unexposed: 250 participants
Access
Availability of data and biosamples
| Possible Access to Data | |
| Possible Access to Biosamples | |
| Other |
Timeline
Populations
The population is composed of highly exposed to COVID-19 virus but uninfected residents of two long-term care facility (LTCF) campuses; Northwood campuses and the St. Vincent campus, in Nova Scotia, Canada.
Selection Criteria
- Newborns
- Twins
- Countries
-
- Canada
- Territory
- Halifax
- Ethnic Origin
-
- Health Status
-
- Other Criteria
-
Inclusion:
Resident of a long-term care facility;
Able to provide consent either directly by the participant, or surrogate in the event of a medical emergency and/or subject who is not capable of providing informed consent;
Able to answer clinical questions and provide medical history directly (the patient) or via a surrogate. - Supplementary Information about selection criteria
- 4 LTCF located in Halifax, Bedford and Chester, Nova Scotia.
Recruitment
- Sources of recruitment
-
- Specific population
- Specific Population
-
- Other specific population : LTCF Residents
- Supplementary Information
-
The study opportunity was advised by medical leadership through written letter and by word of mouth to all long-term care facility residents and their substitute decision makers (SDM) (for those who are unable to provide informed consent). Those residents or SDM who consent to talk with the study team then are contacted by a study team member.
Number of Participants
- Number of Participants
- 48
- Number of Participants with Biological Samples
- 48
Data Collection Events
| # | Name | Description | Start | End |
|---|---|---|---|---|
| 1 |
LIFE-CO - COVID-19 exposed uninfected - Baseline
|
Blood samples were collected by venipuncture for immunity measures. Anti-SARS-CoV-2 spike serology was performed using plasma. After eligibility criteria were reviewed and confirmed, information ... | 2020-12 | 2021-01 |
| 2 |
LIFE-CO - COVID-19 exposed uninfected - Pre-vaccine
|
Blood samples were collected by venipuncture for measures of immunity. Anti-SARS-CoV-2 spike serology was performed using plasma. After eligibility criteria were reviewed and confirmed, ... | 2021-01 | 2021-01 |
| 3 |
LIFE-CO - COVID-19 exposed uninfected - Pre-boost
|
Blood samples were collected by fingerstick for dried blood spot for serology. Information about recent and current medications, COVID-19 assessment such as testing, symptoms, exposures; ... | 2021-02 | 2021-03 |
| 4 |
LIFE-CO - COVID-19 exposed uninfected - 1-month post-boost
|
Blood samples were collected by fingerstick for dried blood spot for serology. Information about recent and current medications, COVID-19 assessment like test, symptoms, exposures; vaccination ... | 2021-03 | 2021-04 |
| 5 |
LIFE-CO - COVID-19 exposed uninfected - 3-months post-boost
|
Blood samples were collected by fingerstick for dried blood spot for serology. Information about current medications, clinical status, COVID-19 assessment like test, symptoms, exposures; ... | 2021-05 | 2021-06 |
| 6 |
LIFE-CO - COVID-19 exposed uninfected - 6-months post-boost
|
Blood samples were collected by venipuncture for measures of immunity. Anti-SARS-CoV-2 spike serology will be performed using plasma. Information about current medications, clinical status ... | 2021-07 | 2021-10 |
| 7 |
LIFE-CO - COVID-19 exposed uninfected - 12-months post-boost
|
Blood samples were collected by venipuncture for measures of immunity. Information about current medications, clinical status (frailty and mobility), COVID-19 assessment like test, symptoms, ... | 2022-01 | 2022-04 |
The population is composed of COVID-19 positive recovered residents of two a long-term care facility (LTCF) campuses; Northwood campuses and the St. Vincent campus, in Nova Scotia, Canada.
Selection Criteria
- Newborns
- Twins
- Countries
-
- Canada
- Territory
- Halifax
- Ethnic Origin
-
- Health Status
-
- Other Criteria
-
Inclusion:
Resident of a long-term care facility;
Able to provide consent either directly by the participant, or surrogate in the event of a medical emergency and/or subject who is not capable of providing informed consent;
Able to answer clinical questions and provide medical history directly (the patient) or via a surrogate. - Supplementary Information about selection criteria
- 4 LTCF located in Halifax, Bedford and Chester, Nova Scotia.
Recruitment
- Sources of recruitment
-
- Specific population
- Specific Population
-
- Other specific population : LTCF Residents
- Supplementary Information
-
The study opportunity was advised by medical leadership through written letter and by word of mouth to all long-term care facility residents and their substitute decision makers (SDM) (for those who are unable to provide informed consent). Those residents or SDM who consent to talk with the study team then are contacted by a study team member.
Number of Participants
- Number of Participants
- 60
- Number of Participants with Biological Samples
- 60
Data Collection Events
| # | Name | Description | Start | End |
|---|---|---|---|---|
| 0 |
LIFE-CO - COVID-19 recovered - Baseline
|
Blood samples were collected by venipuncture for measures of immunity. Information about current medications, clinical status (frailty and mobility), COVID-19 assessment like test, symptoms, ... | 2020-12 | 2021-01 |
| 1 |
LIFE-CO - COVID-19 recovered - Pre-vaccine
|
Blood samples were collected by venipuncture for measures of immunity. Anti-SARS-CoV-2 spike serology was performed using plasma. After eligibility criteria were reviewed and confirmed, ... | 2021-01 | 2021-01 |
| 2 |
LIFE-CO - COVID-19 recovered - Pre-boost
|
Blood samples were collected by fingerstick for dried blood spot for serology. Information about recent and current medications, COVID-19 assessment such as testing, symptoms, exposures; ... | 2021-02 | 2021-03 |
| 3 |
LIFE-CO - COVID-19 recovered - 1-month post-boost
|
Blood samples were collected by fingerstick for dried blood spot for serology. Information about recent and current medications, COVID-19 assessment like test, symptoms, exposures; vaccination ... | 2021-03 | 2021-04 |
| 4 |
LIFE-CO - COVID-19 recovered - 3-months post-boost
|
Blood samples were collected by fingerstick for dried blood spot for serology. Information about current medications, clinical status, COVID-19 assessment like test, symptoms, exposures; ... | 2021-05 | 2021-06 |
| 5 |
LIFE-CO - COVID-19 recovered - 6-months post-boost
|
Blood samples were collected by venipuncture for measures of immunity. Anti-SARS-CoV-2 spike serology will be performed using plasma. Information about current medications, clinical status ... | 2021-07 | 2021-10 |
| 6 |
LIFE-CO - COVID-19 recovered - 12-months post-boost
|
Blood samples were collected for immunity measures and anti-SARS-CoV-2 spike serology. Information on balance and mobility, the Clinical Frailty Scale (CFS) score, current medication lists ... | 2022-01 | 2022-04 |
The population is composed of unexposed to COVID-19 residents of two a long-term care facility (LTCF) campuses; Northwood campuses and the St. Vincent campus, in Nova Scotia, Canada.
Selection Criteria
- Newborns
- Twins
- Countries
-
- Canada
- Territory
- Halifax
- Ethnic Origin
-
- Health Status
-
- Other Criteria
-
Inclusion:
Resident of a long-term care facility;
Able to provide consent either directly by the participant, or surrogate in the event of a medical emergency and/or subject who is not capable of providing informed consent;
Able to answer clinical questions and provide medical history directly (the patient) or via a surrogate. - Supplementary Information about selection criteria
- 4 LTCF located in Halifax, Bedford and Chester, Nova Scotia.
Recruitment
- Sources of recruitment
-
- Specific population
- Specific Population
-
- Other specific population : LTCF Residents
- Supplementary Information
-
The study opportunity was advised by medical leadership through written letter and by word of mouth to all long-term care facility residents and their substitute decision makers (SDM) (for those who are unable to provide informed consent). Those residents or SDM who consent to talk with the study team then are contacted by a study team member.
Number of Participants
- Number of Participants
- 250
- Number of Participants with Biological Samples
- 250
- Supplementary Information about selection criteria
- A subset of the Wave 2 low prevalence cohort (N=60) will be examined for T and B cell immunity and the remainder will be biobanked for future studies aimed at understanding immunity and biomarkers in vulnerable older persons.
Data Collection Events
| # | Name | Description | Start | End |
|---|---|---|---|---|
| 0 |
LIFE-CO - COVID-19 unexposed - Baseline
|
Blood samples were collected by venipuncture for immunity measures. Anti-SARS-CoV-2 spike serology was performed using plasma. After eligibility criteria were reviewed and confirmed, information ... | 2020-12 | 2021-01 |
| 1 |
LIFE-CO - COVID-19 unexposed - Pre-vaccine
|
Blood samples were collected by venipuncture for measures of immunity. Anti-SARS-CoV-2 spike serology was performed using plasma. After eligibility criteria were reviewed and confirmed, ... | 2021-01 | 2021-01 |
| 2 |
LIFE-CO - COVID-19 unexposed - Pre-boost
|
Blood samples were collected by fingerstick for dried blood spot for serology. Information about recent and current medications, COVID-19 assessment such as testing, symptoms, exposures; ... | 2021-02 | 2021-03 |
| 3 |
LIFE-CO - COVID-19 unexposed - 1-month post-boost
|
Blood samples were collected by fingerstick for dried blood spot for serology. Information about recent and current medications, COVID-19 assessment like test, symptoms, exposures; vaccination ... | 2021-03 | 2021-04 |
| 4 |
LIFE-CO - COVID-19 unexposed - 3-months post-boost
|
Blood samples were collected by fingerstick for dried blood spot for serology. Information about current medications, clinical status, COVID-19 assessment like test, symptoms, exposures; ... | 2021-05 | 2021-06 |
| 5 |
LIFE-CO - COVID-19 unexposed - 6-months post-boost
|
Blood samples were collected by venipuncture for measures of immunity. Anti-SARS-CoV-2 spike serology will be performed using plasma. Information about current medications, clinical status ... | 2021-07 | 2021-10 |
| 6 |
LIFE-CO - COVID-19 unexposed - 12-months post-boost
|
Blood samples were collected by venipuncture for measures of immunity. Information about current medications, clinical status (frailty and mobility), COVID-19 assessment like test, symptoms, ... | 2022-01 | 2022-04 |
Classifications
- Socio-demographic and economic characteristics
- Lifestyle and behaviours
- Birth, pregnancy and reproductive health history
- Perception of health, quality of life, development and functional limitations
- Diseases
- Symptoms and signs
- Medication and supplements
- Non-pharmacological interventions
- Health and community care services utilization
- Death
- Physical measures and assessments
- Laboratory measures
- Cognition, personality and psychological measures and assessments
- Life events, life plans, beliefs and values
- Preschool, school and work life
- Social environment and relationships
- Physical environment
- Administrative information
- Perception of health
- Quality of life
- Life course development
- Functional limitations
- Other perception of health, quality of life and functional limitation-related information
Socio-demographic and economic characteristics
Age/birthdate
Sex/gender
Family and household structure
Residence
Ethnicity, race and religion
Lifestyle and behaviours
Tobacco
Leisure activities
Perception of health, quality of life, development and functional limitations
Functional limitations
Diseases
Certain infectious and parasitic diseases (A00-B99)
Neoplasms (C00-D48)
Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism (D50-D89)
Endocrine, nutritional and metabolic diseases (E00-E90)
Diseases of the nervous system (G00-G99)
Diseases of the circulatory system (I00-I99)
Diseases of the respiratory system (J00-J99)
Diseases of the digestive system (K00-K93)
Diseases of the genitourinary system (N00-N99)
Symptoms and signs
Symptoms and signs involving the circulatory and respiratory systems (R00-R09)
Symptoms and signs involving the digestive system and abdomen (R10-R19)
Symptoms and signs involving nervous and musculoskeletal systems (R25-R29)
Symptoms and signs involving cognition, perception, emotional state and behaviour (R40-R46)
General symptoms and signs (R50-R69)
Symptoms related to multiple categories
Medication and supplements
Medication and supplement intake
Posology and protocol of administration
Non-pharmacological interventions
Laboratory diagnosis interventions
Other and unspecified non-pharmacological interventions
Health and community care services utilization
Visits to health professionals
Hospitalizations
Community and social care
Death
Vital status
Physical measures and assessments
Anthropometry
Circulation and respiration
Other physical measures and assessments
Laboratory measures
Hematology
Biochemistry
Virology
Immunology
Social environment and relationships
Social support
Administrative information
Identifiers
Date and time-related information
Questionnaire and interview-related information
Physical and cognitive measure and biosample-related information
Other administrative information
Functional limitations
Long-Term Care Comprehensive Geriatric Assessment